logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: Drugs
Load new posts () and activity
Like Reblog Comment
text 2018-08-08 09:05
Tuberculosis Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis

Worldwide Market Reports added Latest Research Report titled “Tuberculosis Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis”to its Large Report database.

The Global Tuberculosis Drugs Market was valued at US$ 1,389.3 million in 2015 and is projected to expand at a CAGR of 5.9% during the forecast period (2016-2024), as highlighted in a new report published by Coherent Market Insights. Growing prevalence of tuberculosis and increasing tobacco smoking is expected to drive growth of the global tuberculosis drugs market.
Drug shortage to treat tuberculosis is a major challenge to effective healthcare in the U.S., with the shortage of drug number tripling from 2007 to 2012. This factor seems to be troublesome and represents a public health threat. U.S. Government Accountability Office reported that there is 16% shortage of anti-infective drugs, including that for tuberculosis. Various healthcare agencies have organized TB awareness campaigns across the U.S. and had difficulty in accessing medicines and products to diagnose the disease and this is due to shortage, supply disruptions, and high costs of the products. The success story of India drugs market is timely and adequate supply of drugs, though it has been hit the hardest due to poor government policies and tough procurement procedures.
Multidrug-resistant tuberculosis (MDR-TB) is a rising health issue globally. The level and encumbrance of multidrug-resistant tuberculosis differs significantly by region and country. Across the globe, around 3% of all new cases of patients diagnosed with TB have multidrug-resistant tuberculosis and the percentage is more in patients who had already accepted anti-tuberculosis treatment replicating the failure of programs intended to ensure complete cure of patients with tuberculosis. To manage multidrug-resistant tuberculosis is a huge task and that should be accepted by experienced clinicians at centers where there are well-equipped process and with reliable laboratory services and also by implementing the DOTS-Plus strategy.

Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/187569

Asia and Africa provide largely untapped growth avenues for players in the global tuberculosis drugs market
The global spread of tuberculosis cases is tilted predominantly toward low-income and emerging economies countries. The highest prevalence of tuberculosis cases are in Asia, which includes China, India, Bangladesh, Indonesia, and Pakistan contributing 50% of the global tuberculosis burden. Africa is one of the most tuberculosis infested regions globally and unambiguously the sub-Saharan Africa has the highest rate of tuberculosis incidence, with 83 and 290 patients per 100,000, respectively. Tuberculosis cases occur highly between the age group of 15 to 49 year. According to World Health Organization, tuberculosis is projected to yield an annual economic toll of US$12 billion from the income of poor people. Many literature studies explain that the average work time lost by an individual after getting injected by tuberculosis bacteria is around 3-4 months, which further result in a mean lost potential earnings of 20%-30% of the annual household income and over deaths caused by premature tuberculosis deaths the loss of income is ~15 years, estimated by WHO. Thus, the global tuberculosis drugs market is expected to witness steady growth in the foreseeable future.
Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/187569

Key takeaways of the market:
• The global tuberculosis drugs market is expected to expand at a CAGR of 5.9% during the forecast period (2016-2024) as there still exists a major unrealized market, especially in Asia Pacific, Latin America, Middle East and Africa
• The first line drugs therapy dominates the tuberculosis drugs market in the therapy type segment as it is the primary and basic tuberculosis drugs used to treat the patients who are effected with the tuberculosis for the first time
• Incidence of tuberculosis is high in Africa and Asia
• There are 4 new treatment drug in clinical trials. Approval of a new drug could be a major breakthrough in the global tuberculosis drugs market.
• Some of the major players involved in global tuberculosis drugs market are Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd.

**If you have any special requirements, please let us know and we will offer you the report as you want.


About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

#3200

Seattle, WA 98154,

U.S

Tel: +1 415 871 0703

Email: sales@worldwidemarketreports.com

Like Reblog Comment
text 2018-07-27 13:41
Pulmonary Drugs Market Forecast till 2025

Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication. This has led to intensification of efforts for development of effective and efficient pulmonary drugs and medications. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers.

Click To Continue Reading on Pulmonary Drugs Market

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world. The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma.

For instance, according to the Centers of Disease Control and Prevention (CDC) the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015. North America dominates the global pulmonary drugs market, owing to the increasing prescriptions of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.

The government and non-government initiatives help patients to fight the diseases by providing sufficient medical care and education regarding the benefits of preventive measures as well as appropriate medications to curb the life threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1285

Key Vendors:

Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
 #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Like Reblog Comment
text 2018-06-14 12:07
Hepatocellular Carcinoma Drugs Market - Global Industry Insights, 2026

Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy and targeted drug therapy.

 

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1596

 

A majority of the HCC patients are diagnosed at the end-stage of liver dysfunction. Due to poor prognosis of the condition, mortality rate is approximately the same as the incidence rate. Therefore, early detection of the cancer is an important parameter to improve the survival of affected patients, thus aiding in growth of the global hepatocellular carcinoma drugs market.

 

Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin.

 

Click To Continue Reading on Hepatocellular Carcinoma Drugs Market

 

About Coherent Market Insights:

 

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/



Like Reblog Comment
text 2018-05-30 13:16
Cervical Ripening Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Cervical Ripening Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

 

Market Outline: Cervical Ripening Drugs Market

Cervical ripening is defined as the softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening Drugs are used before the induction of labor for the dilatation of cervix. The ripening of cervix is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix. The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins.

 

Market Dynamics: Cervical Ripening Drugs Market

Growing usage of cervical ripening Drugs before the induction of labor, rise in R&D activities for the innovation of newer Drugs, increase in awareness about cervical ripening Drugs in developed and developing countries, low cost of Drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening Drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening Drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening Drugs market over the forecast timeframe.

 

A sample of this report is available upon request @

 https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Market Scope: Cervical Ripening Drugs Market

Cervical ripening Drugs market is segmented on the basis of drug type, route of administration, distribution channel, and region

Based on the drug type, market is segmented into the following:

  • Prostaglandins
  • Oxytocin
  • Progesterone Receptor Antagonists
  • Relaxin
  • Estrogen
  • Others

Based on the route of administration, market is segmented into the following:

  • Oral
  • Intravenous
  • Vaginal

Based on the distribution channel, market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

 

 

To view TOC of this report is available upon request @

 https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/#ulp-c654SbFYO64MsOhu

 

 

Market Summary: Cervical Ripening Drugs Market

Cervical ripening Drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening Drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in cervical ripening Drugs market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.

 

Regional Analysis:  Cervical Ripening Drugs Market

Geographically, global cervical ripening Drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening Drugs market growth driven by increase in the R&D for the innovation of newer Drugs and high awareness about the cervical ripening Drugs among the physicians. Europe cervical ripening Drugs market has a lucrative growth owing to high adoption of cervical ripening Drugs, launching of newer Drugs by the market players. Asia Pacific cervical ripening Drugs market has significant share owing to rise in number of female population, government initiations for the baby birth, and increase in the using of cervical ripening Drugs before the induction of labor are propel the market. Middle East and Africa cervical ripening Drugs market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening Drugs are in the region.

 

Competition Assessment: Cervical Ripening Drugs Market  

Some of the players in the global cervical ripening Drugs market include:

  • Ferring B.V. (Switzerland)
  • Azanta A/S (Denmark)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Bayer AG (Germany)

 

Need more information about this report @

 https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/#ulp-14mlyhjMGhVjZqa3

 

 

Notable Market Developments: Cervical Ripening Drugs Market

  • In February 2016, Azanta A/S filed marketing authorization application in Nordic countries for Angusta (Misoprostol), which is indicated in induction of labor

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2012 to 2016) and forecast (2017 to 2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/

 

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

 

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

 

Contact to Precision Business Insights,

 

Kemp House,

 

152 – 160 City Road,

 

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

Like Reblog Comment
text 2018-05-30 12:21
Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Celiac Disease Pipeline Drugs Assessment

 

Overview:

Celiac Diseaseis a genetic autoimmune disease. It is caused due to the consumption of protein called gluten, which is found in barley, wheat,and rye. It enables damage the finger-like villi of small intestine and body will be unable to absorb nutrients into thebloodstream that leads to malnutrition. Symptoms of celiac disease include food allergy, watery and itchy eyes, difficulty in breathing, nausea, abdominal pain, mouth ulcers.

Celiac disease is diagnosed by serology tests and genetic tests. Treatment includes strict gluten-free diet. There are no FDA approved drugs to treat celiac disease.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By Drugs, Celiac Disease pipeline drugs are segmented as:

  • Larazotide
  • Pancrelipase
  • Rifaximin
  • Triamcinolone
  • Bupivacaine

By Route of Administration, Celiac Disease pipeline drugs are segmented as:

  • Oral
  • Parenteral

By Trial Phase, Celiac Diseasepipeline drugs are segmented as:

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Celiac Diseasepipeline drugs are segmented as:

  • AMYRA Biotech AG (Switzerland)
  • Avaxia Biologics, Inc. (U.S.)
  • Calypso Biotech SA (Switzerland)
  • Provid Pharmaceuticals Inc. (U.S.)
  • Sitari Pharmaceuticals (U.S.)
  • Cour Pharmaceuticals (U.S.)
  • Glenmark Pharmaceuticals Ltd. (India)
  • Innovate Biopharmaceuticals (U.S.)
  • Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

 

Space Analysis:

  • In November 2017, ImmusanT, Inc.raised $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners to proceedPhase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen DQ2.5 (HLA-DQ2.5) immune recognition gene.
  • In February 2016, Innovate Biopharmaceuticals Inc., completed an agreement to license Alba Therapeutics assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.
  • In December 2015, Takeda Pharmaceutical Company Limited and Cour Pharmaceutical Development Company, Inc. entered into a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease
  • In March 2015, Falk Pharma and Zedira entered into a collaboration to perform Phase 1 clinical trials of ED1227, a direct-acting inhibitor of tissue transglutaminase. The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the celiac disease process.

 

Report Description:

Celiac Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Celiac Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Celiac Disease pipeline drugs development. This report studies the dynamics of the Celiac Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Celiac Disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

 

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on each drug candidates in the clinical trial phases

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

 

More posts
Your Dashboard view:
Need help?